Editor's Note: Bladder cancer is one of the common malignant tumors among residents in China, with 75% of bladder cancers being non-muscle-invasive bladder cancer (NMIBC) with a high postoperative recurrence…

Editor’s Note: Endocrine therapy remains one of the standard adjuvant treatments for patients with hormone receptor-positive, HER2-negative (HR+/HER2−) early-stage breast cancer. In recent years, research in this field has made…

Editor’s Note: Anti-HER2 therapy has long been the cornerstone of treatment for patients with HER2-high (IHC 3+ or IHC 2+/FISH+) advanced gastric cancer. In recent years, combining anti-HER2 therapy with…

Editor’s Note: Over the past two decades, clinical research on breast cancer in China has achieved a remarkable transformation — from “following” international standards to “running alongside”, and even “leading”…

Editor’s Note:  On May 29, 2025, the originator, next-generation CDK4/6 inhibitor Lerociclib received approval from China’s National Medical Products Administration (NMPA) for both first-line and second-line indications in HR+/HER2– advanced…

Editor’s Note: As a standard treatment for hormone receptor–positive, HER2–negative metastatic breast cancer (HR+/HER2- MBC), CDK4/6 inhibitors (CDK4/6i) have significantly improved therapeutic outcomes and expanded treatment options. However, developing next-generation…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have become an important therapeutic option for hormone receptor–positive, HER2–negative (HR+/HER2-) breast cancer, yet there remains room for improvement in efficacy and safety.  Recently, the…

Editor’s note: CDK4/6 inhibitors (CDK4/6i) have become a cornerstone of treatment for hormone receptor–positive, HER2-negative (HR+/HER2-) advanced breast cancer and have substantially improved patient outcomes. On 29 May 2025, China’s…